Also known as: Azacytidine

Therapeutic indications

Azacitidine is indicated for:

Myelodysplastic syndromes, chronic myelomonocytic leukaemia, acute myeloid leukaemia

Population group: both men and women, only adults (18 years old or older)

Azacitidine is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:

  • intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
  • chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder,
  • acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,
  • AML with >30% marrow blasts according to the WHO classification.

For this indication, competent medicine agencies globally authorize below treatments (click for details):


Azacitidine is contraindicated in the following cases:



Advanced malignant hepatic tumours

Malignant neoplasm of liver

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines